A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Public ClinicalTrials.gov record NCT06903338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Study identification
- NCT ID
- NCT06903338
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2025
- Primary completion
- Dec 30, 2026
- Completion
- Apr 30, 2031
- Last update posted
- Apr 7, 2026
2025 – 2031
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Chandler | Arizona | 85224 | — |
| Investigative Site | Los Angeles | California | 90033 | — |
| Investigative Site | Redwood City | California | 94063 | — |
| Investigative Site | San Francisco | California | 94143 | — |
| Investigative Site | DeLand | Florida | 32720 | — |
| Investigative Site | Chicago | Illinois | 60612 | — |
| Investigative Site | Baltimore | Maryland | 21287 | — |
| Investigative Site | Hillsborough | New Jersey | 08844 | — |
| Investigative Site | New York | New York | 10016 | — |
| Investigative Site | New York | New York | 10021 | — |
| Investigative Site | New York | New York | 10029 | — |
| Investigative Site | Murray | Utah | 84107 | — |
| Investigative Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06903338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06903338 live on ClinicalTrials.gov.